Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
=== University of Cambridge === The sudden death of British pathologist Thomas Strangeways on 23 December 1926 created a vacancy in the Huddersfield Lectureship in Special Pathology at Cambridge, and it was offered to Florey. At Cambridge, Florey had a secure appointment and fine laboratory facilities, although the salary of £900 (equivalent to £48,000 in 2025) was only slightly higher. He had to teach, which he disliked, preferring research, but there was satisfaction that the new tripos course was largely designed by himself and Alan Nigel Drury. He recruited fourteen-year-old Jim Kent as his assistant. It was the practice at Cambridge that laboratory technicians would rotate through the various laboratory departments, which provided them with thorough training, but was frustrating to the researcher, who had to break in a new assistant every few months. Finding a good one was difficult for Florey; his reputation for hard work, long hours and exacting standards preceded him. He arranged for Kent to be permanently assigned as his assistant, and Kent would remain in the role for the next forty years. The Floreys bought a house in Cambridge, and Florey cycled to work every day, including Sundays, arriving at 10:00, except on class days when he had to be there earlier. Ethel collaborated on two papers, co-written with Drury and Albert Szent-Györgyi respectively, but stopped coming to the laboratory after she became pregnant.
The use of trapezoidal rule in AUC calculation was known in literature by no later than 1975, in J.G. Wagner's Fundamentals of Clinical Pharmacokinetics. A 1977 article compares the "classical" trapezoidal method to a number of methods that take into account the typical shape of the concentration plot, caused by first-order kinetics. Notwithstanding the above knowledge, a 1994 Diabetes Care article by Mary M. Tai entitled "A Mathematical Model for the Determination of Total Area Under Glucose Tolerance and Other Metabolic Curves" purports to have independently discovered the trapezoidal rule. In Tai's response to the later letters to the editors, she explained that the rule was new to her colleagues, who relied on grid-counting. Tai's paper has been discussed as a case of scholarly peer review failure. Despite the number of mathematically superior numerical integration schemes (such as those outlined in Wagner & Ayres 1977), the trapezoidal rule remains the convention for AUC calculation. Later focus on improving the accuracy of AUC calculation shifted from improving the method to improving the sampling scheme. An example is a 2019 algorithm known as OTTER: it performs a fit onto sum of exponentials curve for the input data but only uses it to suggest better sample times by finding more highly sloped periods.
The neptunium antimonide compound NpSb was produced in 1971 by placing equal quantities of both elements in a vacuum tube, heating them to the melting point of antimony, and then heating it further to 1000 °C for sixteen days. This procedure also produced trace amounts of an additional antimonide compound Np3Sb4. One neptunium-bismuth compound, NpBi, has also been reported. The neptunium carbides NpC, Np2C3, and NpC2 (tentative) have been reported, but have not characterized in detail despite the high importance and utility of actinide carbides as advanced nuclear reactor fuel. NpC is a non-stoichiometric compound, and could be better labelled as NpCx (0.82 ≤ x ≤ 0.96). It may be obtained from the reaction of neptunium hydride with graphite at 1400 °C or by heating the constituent elements together in an electric arc furnace using a tungsten electrode. It reacts with excess carbon to form pure Np2C3. NpC2 is formed from heating NpO2 in a graphite crucible at 2660–2800 °C.
Sources: en.wikipedia.org
The reason for using one or more housekeeping genes is to correct non-specific variation, such as the differences in the quantity and quality of RNA used, which can affect the efficiency of reverse transcription and therefore that of the whole PCR process. However, the most crucial aspect of the process is that the reference gene must be stable. The selection of these reference genes was traditionally carried out in molecular biology using qualitative or semi-quantitative studies such as the visual examination of RNA gels, northern blot densitometry or semi-quantitative PCR (PCR mimics). Now, in the genome era, it is possible to carry out a more detailed estimate for many organisms using transcriptomic technologies. However, research has shown that amplification of the majority of reference genes used in quantifying the expression of mRNA varies according to experimental conditions. It is therefore necessary to carry out an initial statistically sound methodological study in order to select the most suitable reference gene. A number of statistical algorithms have been developed that can detect which gene or genes are most suitable for use under given conditions. Those like geNORM or BestKeeper can compare pairs or geometric means for a matrix of different reference genes and tissues. The entire qPCR analysis workflow with proper error propagations is implemented in GenEx.
For services to Safety at Sea. Derek Baum. For services to the Association of Jewish ex-Servicemen and Women. Donald James MacDonald Beaton, Shepherd, Roslin Institute. For services to Scientific Research. Mary Loveday Beazley. For services to the community in Wormley, Hertfordshire. Marian Beckett, Assistant Caretaker, Priestley College, Warrington, Cheshire. For services to Education. Howard Philip Bell, Honorary Liaison Officer (Eastern Region), Royal National Lifeboat Institution. For services to the RNLI. Clarice Mary Bennett. For services to the British Red Cross Society in Norfolk. Thelma Berry. For services to the Norfolk Foster Care Association. David Wyn Bevan. For services to Industrial Relations in Wales. Mary Winifred Bevan. For services to the NSPCC in Merthyr Tydfil. Deirdre Bevis, Administrative Officer, Ministry of Defence. Fred Billingsley, Higher Professional and Technology Officer, Ministry of Defence. Anthea Billington, Secretary to the Managing Director, Britannia Airways Ltd. For services to the Aviation Industry. Margaret Elizabeth Bingham. For services to Tourism. Jean Shirley Bird, Range B, Her Majesty's Treasury. Edward John Birkett. For services to the community in Canning Town, London. Brian Anthony Blackshaw, Sub-Divisional Officer, West Mercia Special Constabulary. For services to the Police. Mary Elizabeth Bloomer. For services to the community. Christine Boddy. For political service. William Charles Boddy, Founder and Editor, Motor Sport. For services to Sports Journalism. Barbara May Bolton.
A similar stele fragment (ES 1027), 57 centimeters high by 42 centimeters wide by 20 deep, depicting Naram-Sin was found a few miles north-east of Diarbekr, at Pir Hüseyin in a well, though this was not its original context. It is said to have been first found in Miyafarkin, a village about 75 kilometers northeast of Diarbekr. Fragments of an alabaster stele representing captives being led by Akkadian soldiers is sometimes attributed to Narim-Sin (or Rimush or Manishtushu) on stylistic grounds. In particular, it is considered as more sophisticated graphically than the steles of Sargon of Akkad or those of Rimush or Manishtushu. Two fragments (IM 55639 and IM 59205) are in the National Museum of Iraq, and one (MFA 66.89) is the Boston Museum. The stele is quite fragmentary, but attempts at reconstitution have been made. Depending on sources, the fragments were excavated in Wasit, al-Hay district, Wasit Governorate, or in Nasiriyah, both locations in Iraq. It is thought that the stele represents the result of the campaigns of Naram-Sin to Cilicia or Anatolia. This is suggested by the characteristics of the booty carried by the soldiers in the stele, especially the metal vessel carried by the main soldier, the design of which is unknown in Mesopotamia, but on the contrary well known in contemporary Anatolia.
Zita of Bourbon-Parma (Zita Maria delle Grazie Adelgonda Micaela Raffaela Gabriella Giuseppina Antonia Luisa Agnese; 9 May 1892 – 14 March 1989) was the last Empress of Austria and Queen of Hungary, in addition to other titles. She ascended to these titles when her husband, Charles I, became the last monarch of Austria-Hungary. She was declared Servant of God by Pope Benedict XVI. Born as the seventeenth child of the dispossessed Robert I, Duke of Parma, by his second wife, Infanta Maria Antonia of Portugal, Zita married Archduke Charles of Austria in 1911. Charles became heir presumptive to Emperor Franz Joseph I in 1914 after the assassination of his uncle Archduke Franz Ferdinand of Austria, and acceded to the throne in 1916 after the elderly emperor's death. After the end of World War I in 1918, the Habsburgs were deposed and the former empire became home to the states of Austria, Hungary, and Czechoslovakia, while other parts were annexed to or joined the Kingdom of the Serbs, Croats and Slovenes, Italy, Romania, and a reconstituted independent Poland. Charles and Zita left for exile in Switzerland and, after the failure of attempts to restore royal rule in Hungary, were subsequently removed from that country by the Allies to Madeira, where Charles died in 1922. After her husband's death, Zita and her son Otto served as symbols of unity for the exiled dynasty. A devout Catholic, she raised a large family after being widowed at the age of 29; she never remarried.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.